Fuan Pharmaceutical Group Co Asset Resilience Ratio
Fuan Pharmaceutical Group Co asset resilience ratio. Fuan Pharmaceutical Group Co (300194) has an Asset Resilience Ratio of 3.02% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Fuan Pharmaceutical Group Co fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Fuan Pharmaceutical Group Co (2015–2025)
Asset resilience ratio of Fuan Pharmaceutical Group Co from 2015 to 2025. This chart shows how Fuan Pharmaceutical Group Co's Asset Resilience Ratio has changed over time. Read 300194 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Fuan Pharmaceutical Group Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Fuan Pharmaceutical Group Co balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥170.12 Million | 3.02% |
| Total Liquid Assets | CN¥170.12 Million | 3.02% |
Asset Resilience Insights
- Limited Liquidity: Fuan Pharmaceutical Group Co maintains only 3.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Fuan Pharmaceutical Group Co Industry Peers by Asset Resilience Ratio
Compare Fuan Pharmaceutical Group Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Fuan Pharmaceutical Group Co Asset Resilience Ratio by Year (2015–2025)
Fuan Pharmaceutical Group Co asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Fuan Pharmaceutical Group Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.60% | CN¥150.05 Million ≈ $21.96 Million |
CN¥5.76 Billion ≈ $843.37 Million |
+2.10pp |
| 2024-12-31 | 0.50% | CN¥30.00 Million ≈ $4.39 Million |
CN¥5.98 Billion ≈ $874.85 Million |
+0.42pp |
| 2023-12-31 | 0.08% | CN¥5.05 Million ≈ $739.50K |
CN¥5.98 Billion ≈ $874.47 Million |
-0.17pp |
| 2022-12-31 | 0.26% | CN¥15.21 Million ≈ $2.23 Million |
CN¥5.88 Billion ≈ $860.13 Million |
-0.11pp |
| 2021-12-31 | 0.37% | CN¥20.86 Million ≈ $3.05 Million |
CN¥5.71 Billion ≈ $835.03 Million |
-0.90pp |
| 2020-12-31 | 1.27% | CN¥75.67 Million ≈ $11.07 Million |
CN¥5.97 Billion ≈ $874.01 Million |
-2.90pp |
| 2019-12-31 | 4.17% | CN¥197.31 Million ≈ $28.87 Million |
CN¥4.74 Billion ≈ $693.02 Million |
+2.86pp |
| 2018-12-31 | 1.30% | CN¥56.00 Million ≈ $8.19 Million |
CN¥4.29 Billion ≈ $628.14 Million |
-6.10pp |
| 2017-12-31 | 7.40% | CN¥347.00 Million ≈ $50.78 Million |
CN¥4.69 Billion ≈ $686.12 Million |
+3.28pp |
| 2016-12-31 | 4.12% | CN¥181.00 Million ≈ $26.49 Million |
CN¥4.40 Billion ≈ $643.51 Million |
-11.07pp |
| 2015-12-31 | 15.18% | CN¥376.42 Million ≈ $55.08 Million |
CN¥2.48 Billion ≈ $362.77 Million |
-- |
About Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China and internationally. It offers APIs; intermediates; and FDFs, such as anti-tumor, specialty drugs, antibiotics, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) … Read more